Difference between revisions of "Brentuximab vedotin (Adcetris)"
(Created page with "'''FDA approved 8/19/2011''' ==General information== Class/mechanism: Anti-CD30 antibody (brentuximab) with protease-cleavable linker to chemotherapeutic agent (monomethyl auris...") |
|||
| Line 2: | Line 2: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Anti-CD30 antibody (brentuximab) with protease-cleavable linker to chemotherapeutic agent (monomethyl auristatin E (MMAE, vedotin)). The antibody-drug complex binds to CD30 expressing cells and is internalized, where the active chemotherapeutic agent MMAE is released via proteolytic cleavage of the antibody-drug linker. MMAE is a microtubule disrupting agent that interferes with mitosis, causes cell cycle arrest, and eventual apoptosis.<ref name="insert">[http://www.adcetris.com/_pdf/ | + | Class/mechanism: Anti-CD30 antibody (brentuximab) with protease-cleavable linker to chemotherapeutic agent (monomethyl auristatin E (MMAE, vedotin)). The antibody-drug complex binds to CD30 expressing cells and is internalized, where the active chemotherapeutic agent MMAE is released via proteolytic cleavage of the antibody-drug linker. MMAE is a microtubule disrupting agent that interferes with mitosis, causes cell cycle arrest, and eventual apoptosis.<ref name="insert">[http://www.adcetris.com/_pdf/Final_Adcetris_USPI_Jan12_2012.pdf Brentuximab vedotin (Adcetris) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/brentuximabvedotin.pdf Brentuximab vedotin (Adcetris) package insert (locally hosted backup)]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
Revision as of 20:55, 22 February 2012
FDA approved 8/19/2011
General information
Class/mechanism: Anti-CD30 antibody (brentuximab) with protease-cleavable linker to chemotherapeutic agent (monomethyl auristatin E (MMAE, vedotin)). The antibody-drug complex binds to CD30 expressing cells and is internalized, where the active chemotherapeutic agent MMAE is released via proteolytic cleavage of the antibody-drug linker. MMAE is a microtubule disrupting agent that interferes with mitosis, causes cell cycle arrest, and eventual apoptosis.[1][2]
Route: IV
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].